Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 4, 1995 - Issue 10
Submit an article Journal homepage
4
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Monthly Update Cardiovascular & Renal: Treating hypertension with angiotensin II receptor antagonists: What have we learned?

Salah D Kivlighn Department of Pharmacology, Merck Research Laboratories, West Point, PA, 19486, USA
&
Peter KS Siegl Department of Pharmacology, Merck Research Laboratories, West Point, PA, 19486, USA
Pages 1013-1015 | Published online: 03 Mar 2008

References

  • KAPLAN NM: Systemic hypertension: mechanisms and diagnosis. In: Heart Disease. Braunwald E (Ed.). WI3 Saun-ders (1992).
  • World Health Organization Bulletin (1993) 71(5):503–517.
  • CHRISTEN Y, WAEBER B, NUSSBERGER J, ET AL.: Oral administration of DuP 753, a specific angiotensin II receptor antagonist to normal male volunteers. Inhibi-tion of pressor response to exogenous anglotensin I and U. Circulation (1991) 83:1333–1342.
  • GOLDBERG A: Efficacy and safety of losartan. Can. J. Cardiol. (1995) 11(Suppl. E). In Press.
  • DAHLOF B, KELLER SE, MAKRIS L: Efficacy and tolerabil-ity of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am. J. Hyper-tens. (1995) 8:578–583.
  • GRADMAN All, ARCURI KE, GOLDBERG AL, ET AL.: A randomized, placebo-controlled double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hyper-tension. Hypertens. (1995) 25:1345–1350.
  • NELSON EB, MERRILL DM, SWEET CS, ETAL.: Efficacy and safety of oral MK-954 (DuP 753), an angiotensin recep-tor antagonist, in essential hypertension. J. Hypertens. (1991) 9\(Suppl. 6):S468–S469–
  • GOLDBERG AL, DUNLAY MC, SWEET CS: Safety and tol-erability of losartan potassium, an angiotensin receptor antagonist, compared with hydrochlorothiazicle, atenolol, felodipine ER and angiotensin-converting en-zyme inhibitors for the treatment of systemic hyper-tension. Am. J. Cardiol. (1995) 75:793–795.
  • SACHINIDID A, KO Y, WEISSER P, ETAL.: EXP 3174, a metabolite of losartan (MK-954, DuP 753) is more po-tent than losartan in blocking the angiotensin 11 in-duced responses in vascular smooth muscle cells. J. Hypertens. (1993) 11:155–162.
  • LO M-W, LU H, FARRELL DM, ETAL.: Pharmacokinetics of Intravenous EXP-3174, an active metabolite of losartan In man. Pharm. Res. (1992) 9:S308.
  • SWEET CS, BRADSTREET DC, BERMAN RS, ETAL.: Pharma-codynarnic activity of intravenous E-3174, an angioten-sin II antagonist, in patients with essential hypertension. Am. J. Hypertens. (1994) 7:1035–1040.
  • SRAMEK JJ, CUTLER NR, SEIFERT RD, ETAL.: Compliance In hypertension: Daily vs. twice daily. Am. J. Hypertens. (1993) 6:1063.
  • HUCKLE WR, EARP HS: Regulation of cell proliferationand growth by angiotensin U. Prog. Growth Factor Res. (1994) 5:177–194.
  • HUSAIN A: The chymase angiotensin system in humans.Hypertens. (1993) 11:1155–1159.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.